2 1 Shi Ji Jing Ji Bao Dao·2026-01-13 02:07Core Viewpoint - The A-share innovative drug sector is experiencing a strong performance, with significant gains in various stocks and active trading in related ETFs [1][2]. Group 1: ETF Performance - The innovative drug ETF (159992) has risen over 2% with a trading volume exceeding 200 million yuan, indicating active market participation [2]. - Notable stocks within the ETF include Rongchang Biopharma, which increased by over 16%, and Tigermed, which rose by over 6% [2]. Group 2: Fund Flows - According to Wind data, the innovative drug ETF has seen a continuous net inflow of funds over the past five trading days, accumulating nearly 900 million yuan [3]. - The ETF closely tracks the CSI Innovative Drug Industry Index, which selects up to 50 representative companies involved in innovative drug research and development based on market capitalization [3]. Group 3: Industry Developments - At the 44th JPMorgan Global Healthcare Conference, NVIDIA and Eli Lilly announced a joint investment of 1 billion USD over five years to establish a research lab in the San Francisco Bay Area, aimed at accelerating AI applications in the pharmaceutical industry [3]. - WuXi AppTec (603259.SH) has forecasted a net profit of 19.151 billion yuan for 2025, representing a year-on-year increase of approximately 102.65% [3]. Group 4: Market Outlook - Guosen Securities emphasizes the importance of the JPMorgan conference and the clinical progress of innovative drugs overseas, highlighting a long-term positive trend in China's innovative drug industry [3]. - The explosive growth in business development (BD) transactions in recent years reflects the industry's potential, with many domestic innovative drugs serving as starting points for global development [3].